The Anti-SARS-CoV-2 ELISAs for immunoglobulin classes A and G and the RT-PCR test EURORealTime SARS-CoV-2 from EUROIMMUN, a PerkinElmer, Inc. company (NYSE:PKI), have received the CE mark and can now be applied to COVID-19 diagnostics.
As the demand for reliable COVID-19 diagnostic tests is steadily increasing, EUROIMMUN is working to expand the test production.
“The worldwide demand for these tests is very high. We will do our best to respond to this need with effective testing solutions”,
says EUROIMMUN’s CEO, Dr. Wolfgang Schlumberger.
Serological tests, on the other hand, like the ELISA, detect antibodies in the blood. This means they are applied when an immune reaction to the pathogen has already taken place.
“The ELISAs are suited for screening on a large scale in order to identify persons who may have had contact with the virus even without noticing, have had an immune response, and have probably developed immunity”,
explains Katja Steinhagen, Head of EUROIMMUN’s Business Division Immunobiochemistry Infectious Serology.
RT-PCR technology plays a role especially in the early stage of a viral infection, in which the virus reproduces quickly.
“The EURORealTime SARS-CoV-2 was developed for specific detection of the novel coronavirus. Because the test detects two different genetic sequences of the virus simultaneously, it is very sensitive”,
explains Dr. Ulf Steller, Head of EUROIMUN’s Business Division Molecular Genetic Diagnostics.
Please download the latest product flyer or read previous notifications from our company.
Lübeck, 31 March 2020
Lübeck, 26 March 2020
Lübeck, 25 March 2020
EUROIMMUN develops and produces test systems for doctors and laboratories that cannot be performed by private individuals.